Treatment of Proven or Probable Invasive Pulmonary Aspergillosis

This protocol addresses the management of patients with invasive pulmonary aspergillosis (IPA) in whom the diagnosis has been established as proven or probable — a clinically critical distinction that shapes treatment selection.

Clinical Scenario

Patients with proven or probable invasive pulmonary aspergillosis. This classification reflects a high level of diagnostic certainty and guides the choice of antifungal therapy, including consideration of azole-resistant organisms.

Treatment Approach (partial)

The protocol specifies liposomal amphotericin B as a second-line antifungal option in this setting. The complete regimen — including the clinical indications that determine when this agent is used, and the full administration details — is available in the structured protocol.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1183/16000617.0114-2022

Triazoles (voriconazole, isavuconazole or posaconazole) should be privileged for proven or probable IPA and liposomal amphotericin B for possible IPA to ensure broad coverage including the Mucorales and azole-resistant Aspergillus species.

Liposomal amphotericin B is a second-line therapy of IPA and the first-line therapy for azole-resistant IPA.

View source ↗